MedMira Rapid HIV Screening Test Achieves 100% in University of Nairobi KAVI Performance Evaluation

	    3-Minute Test Will Increase Efficiencies and Cost Savings in Kenya's
Initiative to Test 8 Million People

	    HALIFAX, June 1 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer of rapid diagnostic technology and solutions,
announced today that the Company is making further progress in bringing the
world's fastest rapid HIV test to the Kenyan market. MedMira's 3-minute Reveal
Rapid HIV Antibody Test (Reveal HIV) recently underwent a performance
evaluation with the University of Nairobi's Kenya AIDS Vaccine Initiative
(KAVI).
	    In the study evaluating the performance of Reveal HIV and comparing its
sensitivity, specificity, and clinical utility side-by-side with the current
reference rapid tests approved for Kenya's national HIV testing algorithm,
Reveal HIV achieved 100%. The KAVI report concludes that the main advantage
Reveal HIV has is the testing procedure is completed and the results obtained
within 3 minutes. Most, if not all rapid HIV tests in the Kenyan market take
from 15 to 60 minutes to obtain the results.
	    "In collaboration with Vitest and Advance Aid, our partners in Kenya, we
are making swift progress in introducing our Reveal rapid HIV test in Kenya.
Evaluations and approvals are always key components of our market entry plans
and this KAVI evaluation is a major step forward in Kenya," said Hermes Chan,
CEO, MedMira Inc.
	    Chan continued "With a program underway to test eight million people in
2010, we know that our 3-minute rapid HIV test can make a major contribution
to Kenya's testing initiatives. Reducing false results rates and improving the
testing capacity of each counselor by 10 to 20 times translates into better
use of resources and successful programs. Reveal HIV delivers the quality and
speed needed to accomplish this."
	    As with many large scale testing campaigns, Kenya's national door-to-door
drive to test 80% of its population in 2010 is not without challenges,
including labour shortages and quality products. According to recent reports,
hundreds and perhaps thousands of Kenyans and Ugandans received false test
results at voluntary counselling and testing centres in Nairobi due to a
faulty 15-minute rapid HIV test.
	    "We are delighted with the excellent results of the KAVI examination and
with the endorsement that this gives to the MedMira product," says David
Dickie, CEO of Advance Aid. "Time is money when you are testing eight million
people and we are very excited to be working with MedMira and Vitest to
market, and ultimately manufacture, Reveal HIV in Kenya."
	    The KAVI evaluation report is now under review with the National AIDS and
Sexually Transmitted Infections Control Programme, the next step in the
approval process in Kenya. The report is available on the MedMira website at
www.medmira.com/africa.

	    About Advance Aid

	    Advance Aid is a UK-registered charity dedicated to creating jobs in
Africa through a radical re-deployment of the world's emergency relief and
development budgets. Our mission is to change the model for emergency relief
and development in Africa to make it more effective for the recipients and to
create sustainable economic and social benefits for the people of sub-Saharan
Africa through job creation and enterprise development. This involves
improving disaster preparedness by significantly increasing the
pre-positioning of non-food emergency relief goods, so that they are in place,
close to potential disaster areas, in advance of any emergency. And, wherever
possible, manufacturing development products and emergency relief goods for
Africa in Africa. For more information visit www.advanceaid.org.

	    About MedMira

	    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals with reliable, rapid diagnosis for diseases such as HIV and
hepatitis C in just three minutes. The company's tests are sold under the
Reveal(R), Multiplo(TM) and Miriad brands in global markets. MedMira's rapid
HIV test is the only one in the world to achieve regulatory approvals in
Canada, the United States, China and the European Union. MedMira's corporate
offices and manufacturing facilities are located in Halifax, Nova Scotia,
Canada. For more information visit MedMira's website at www.medmira.com.

	    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

	    The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.





-30-

	    /For further information: Andrea Young, Corporate Communications,
MedMira, (902) 450-1588, ayoung@medmira.com/